FOLD Q3 2023 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$104M+26.7% YoY

Gross Profit

$94M90.4% margin

Operating Income

-$17M-16.4% margin

Net Income

-$22M-20.8% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+9.5%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$40M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$764M

Total Liabilities

$631M

Stockholders' Equity

$133M

Cash & Equivalents

$263M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$104M	$82M	+26.7%
Gross Profit	$94M	$68M	+37.1%
Operating Income	-$17M	-$34M	+49.7%
Net Income	-$22M	-$33M	+35.2%

Geographic Segments

Non-US

$66M63%

UNITED STATES

$38M37%